Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical trial design as well as provide utility for oncologists in the personalized therapeutic management of individual cancers through identifying novel biomarkers and druggable targets. Rapid advancement of targeted mass spectrometry platforms is underway to integrate phosphoproteomic technology with genomic assays to soon translate this information into the cancer clinic.
Clinical and translational medicine. 2017 Feb 14 [Epub]
Larry C Cheng, Victor M Tan, Shridar Ganesan, Justin M Drake
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08901, USA., Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08901, USA. .